entertainment -WSS

entertainment

author：leisure time 2025-09-03 12:06:11 - browse：82569

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Bispecific antibodies are next new thing in cancer immunotherapy

hotspot

WSS

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Eli Lilly’s Mounjaro succeeds in second weight

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Can medical device makers keep up in the race to treat obesity?

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Streamlined flu vaccines recommended by FDA advisory panel

leisure time

entertainment

knowledge

Bright Health sells Medicare Advantage business to Molina

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price negotiation continues, as pharma counteroffers

Medicare details structure of new drug price negotiation program

The untold story of TV’s first prescription drug ad

DIEP, the 'gold standard' of breast reconstruction, is under threat

Reanimated hearts work just as well for transplants, study finds

ChatGPT in medicine: STAT answers readers' burning questions

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

leisure time

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Medicare drug price negotiation hearing pits pharma v Biden admin

Can medical device makers keep up in the race to treat obesity?

Can medical device makers keep up in the race to treat obesity?

Change Healthcare: What is it, why does its cyberattack matter?

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

hotspot

hotspot

explore

focus